Interleukin-6 in Spinal Cord Injury: Could Immunomodulation Replace Immunosuppression in the Management of Acute Traumatic Spinal Cord Injuries?

Abstract

Traumatic spinal cord injuries (SCI) result in devastating impairment to an individual's functional ability. The pathophysiology of SCI is related to primary injury but further propagated by secondary reactions to injury, such as inflammation and oxidation. The inflammatory and oxidative cascades ultimately cause demyelination and Wallerian degeneration. Currently, no treatments are available to treat primary or secondary injury in SCI, but some studies have shown promising results by lessening secondary mechanisms of injury. Interleukins (ILs) have been described as key players in the inflammation cascade after neuronal injury; however, their role and possible inhibition in the context of acute traumatic SCIs have not been widely studied. Here, we review the relationship between SCI and IL-6 concentrations in the CSF and serum of individuals after traumatic SCIs. Furthermore, we explore the dual IL-6 signaling pathways and their relevance for future IL-6 targeted therapies in SCI.

Keywords

spinal cord injury - interleukin-6 - neuroinflammation - trauma - pathophysiology

Publikationsverlauf

Eingereicht: 24. August 2022

Angenommen: 14. Juni 2023

Accepted Manuscript online:
16. Juni 2023

Artikel online veröffentlicht:
03. Juli 2024

• References

• 1 Lim SW, Shiue YL, Ho CH. et al. Anxiety and depression in patients with traumatic spinal cord injury: a nationwide population-based cohort study. PLoS One 2017; 12 (01) e0169623
• 2 National Spinal Cord Injury Statistical Center. Facts and Figures at a Glance. Birmingham, AL: University of Alabama at Birmingham; 2021
• 3 Lo J, Chan L, Flynn S. A systematic review of the incidence, prevalence, costs, and activity and work limitations of amputation, osteoarthritis, rheumatoid arthritis, back pain, multiple sclerosis, spinal cord injury, stroke, and traumatic brain injury in the United States: a 2019 update. Arch Phys Med Rehabil 2021; 102 (01) 115-131
• 4 Chio JCT, Xu KJ, Popovich P, David S, Fehlings MG. Neuroimmunological therapies for treating spinal cord injury: evidence and future perspectives. Exp Neurol 2021; 341: 113704
• 5 Fehlings MG, Wilson JR, Harrop JS. et al. Efficacy and safety of methylprednisolone sodium succinate in acute spinal cord injury: a systematic review. Global Spine J 2017; 7 (03) 116S-137S
• 6 Liu Z, Yang Y, He L. et al. High-dose methylprednisolone for acute traumatic spinal cord injury: a meta-analysis. Neurology 2019; 93 (09) e841-e850
• 7 Wilson JR, Fehlings MG. Riluzole for acute traumatic spinal cord injury: a promising neuroprotective treatment strategy. World Neurosurg 2014; 81 (5–6): 825-829
• 8 Chow DS, Teng Y, Toups EG. et al. Pharmacology of riluzole in acute spinal cord injury. J Neurosurg Spine 2012; 17 (01) 129-140
• 9 Ahuja CS, Nori S, Tetreault L. et al. Traumatic spinal cord injury—repair and regeneration. Neurosurgery 2017; 80 (3S): S9-S22
• 10 Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. BioMed Res Int 2014; 2014: 698313
• 11 Monsour M, Croci DM, Grüter BE, Taussky P, Marbacher S, Agazzi S. Cerebral aneurysm and interleukin-6: a key player in aneurysm generation and rupture or just one of the multiple factors?. Transl Stroke Res 2023; 14: 631-639
• 12 Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta 2016; 1863 (6 Pt A): 1218-1227
• 13 Schuett H, Oestreich R, Waetzig GH. et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2012; 32 (02) 281-290
• 14 Hirota H, Kiyama H, Kishimoto T, Taga T. Accelerated nerve regeneration in mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. J Exp Med 1996; 183 (06) 2627-2634
• 15 Chucair-Elliott AJ, Conrady C, Zheng M, Kroll CM, Lane TE, Carr DJ. Microglia-induced IL-6 protects against neuronal loss following HSV-1 infection of neural progenitor cells. Glia 2014; 62 (09) 1418-1434
• 16 Yang P, Wen H, Ou S, Cui J, Fan D. IL-6 promotes regeneration and functional recovery after cortical spinal tract injury by reactivating intrinsic growth program of neurons and enhancing synapse formation. Exp Neurol 2012; 236 (01) 19-27
• 17 Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1/M2 polarization. Eur J Pharmacol 2020; 877: 173090
• 18 Guerrero AR, Uchida K, Nakajima H. et al. Blockade of interleukin-6 signaling inhibits the classic pathway and promotes an alternative pathway of macrophage activation after spinal cord injury in mice. J Neuroinflammation 2012; 9: 40
• 19 Ma SF, Chen YJ, Zhang JX. et al. Adoptive transfer of M2 macrophages promotes locomotor recovery in adult rats after spinal cord injury. Brain Behav Immun 2015; 45: 157-170
• 20 Cao Z, Gao Y, Bryson JB. et al. The cytokine interleukin-6 is sufficient but not necessary to mimic the peripheral conditioning lesion effect on axonal growth. J Neurosci 2006; 26 (20) 5565-5573
• 21 Monsour M, Croci DM, Agazzi S. The role of IL-6 in TBI and PTSD, a potential therapeutic target?. Clin Neurol Neurosurg 2022; 218: 107280
• 22 Fernández M, Baldassarro VA, Capirossi R. et al. Possible strategies to optimize a biomarker discovery approach to correlate with neurological outcome in patients with spinal cord injury: a pilot study. J Neurotrauma 2020; 37 (03) 431-440
• 23 Yang L, Blumbergs PC, Jones NR, Manavis J, Sarvestani GT, Ghabriel MN. Early expression and cellular localization of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in human traumatic spinal cord injury. Spine 2004; 29 (09) 966-971
• 24 Kwon BK, Stammers AM, Belanger LM. et al. Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J Neurotrauma 2010; 27 (04) 669-682
• 25 de Mello Rieder M, Oses JP, Kutchak FM. et al. Serum biomarkers and clinical outcomes in traumatic spinal cord injury: prospective cohort study. World Neurosurg 2019; 122: e1028-e1036
• 26 Roberts TT, Leonard GR, Cepela DJ. Classifications In Brief: American Spinal Injury Association (ASIA) Impairment Scale. Clin Orthop Relat Res 2017; 475 (05) 1499-1504
• 27 Kwon BK, Streijger F, Fallah N. et al. Cerebrospinal fluid biomarkers to stratify injury severity and predict outcome in human traumatic spinal cord injury. J Neurotrauma 2017; 34 (03) 567-580
• 28 Dalkilic T, Fallah N, Noonan VK. et al. Predicting injury severity and neurological recovery after acute cervical spinal cord injury: a comparison of cerebrospinal fluid and magnetic resonance imaging biomarkers. J Neurotrauma 2018; 35 (03) 435-445
• 29 Capirossi R, Piunti B, Fernández M. et al. Early CSF biomarkers and late functional outcomes in spinal cord injury. a pilot study. Int J Mol Sci 2020; 21 (23) 9037
• 30 Uciechowski P, Dempke WCM. Interleukin-6: a masterplayer in the cytokine network. Oncology 2020; 98 (03) 131-137
• 31 Hu JG, Shi LL, Chen YJ. et al. Differential effects of myelin basic protein-activated Th1 and Th2 cells on the local immune microenvironment of injured spinal cord. Exp Neurol 2016; 277: 190-201
• 32 Mukaino M, Nakamura M, Yamada O. et al. Anti-IL-6-receptor antibody promotes repair of spinal cord injury by inducing microglia-dominant inflammation. Exp Neurol 2010; 224 (02) 403-414
• 33 Guptarak J, Wanchoo S, Durham-Lee J. et al. Inhibition of IL-6 signaling: A novel therapeutic approach to treating spinal cord injury pain. Pain 2013; 154 (07) 1115-1128
• 34 Leibinger M, Zeitler C, Gobrecht P, Andreadaki A, Gisselmann G, Fischer D. Transneuronal delivery of hyper-interleukin-6 enables functional recovery after severe spinal cord injury in mice. Nat Commun 2021; 12 (01) 391
• 35 Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer 2021; 21 (08) 481-499
• 36 Hellenbrand DJ, Quinn CM, Piper ZJ, Morehouse CN, Fixel JA, Hanna AS. Inflammation after spinal cord injury: a review of the critical timeline of signaling cues and cellular infiltration. J Neuroinflammation 2021; 18 (01) 284
• 37 Biggioggero M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther 2018; 13: 57-70
• 38 Bijlsma JWJ, Welsing PMJ, Woodworth TG. et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 2016; 388 (10042): 343-355
• 39 Bongartz T. Tocilizumab for rheumatoid and juvenile idiopathic arthritis. Lancet 2008; 371 (9617) 961-963
• 40 Hill JA, Menon MP, Dhanireddy S. et al. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. J Med Virol 2021; 93 (04) 2270-2280
• 41 Wise J. Covid-19: arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows. BMJ 2021; 372 (433) n433
• 42 Zhao M, Lu J, Tang Y, Dai Y, Zhou J, Wu Y. Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies. Eur J Clin Pharmacol 2021; 77 (03) 311-319
• 43 Croci DM, Wanderer S, Strange F. et al. Tocilizumab reduces vasospasms, neuronal cell death, and microclot formation in a rabbit model of subarachnoid hemorrhage. Transl Stroke Res 2021; 12 (05) 894-904